USD 26.0
(-2.11%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 6.04 Billion USD | -2.17% |
2022 | 6.17 Billion USD | 17.09% |
2021 | 5.27 Billion USD | -9.59% |
2020 | 5.83 Billion USD | 6.11% |
2019 | 5.49 Billion USD | 3.42% |
2018 | 5.31 Billion USD | -2.62% |
2017 | 5.45 Billion USD | -31.02% |
2016 | 7.91 Billion USD | -12.64% |
2015 | 9.05 Billion USD | 74.64% |
2014 | 5.18 Billion USD | 71.84% |
2013 | 3.01 Billion USD | 39.0% |
2012 | 2.17 Billion USD | 30.95% |
2011 | 1.65 Billion USD | -17.26% |
2010 | 2 Billion USD | 24.14% |
2009 | 1.61 Billion USD | -1.64% |
2008 | 1.64 Billion USD | 40.21% |
2007 | 1.17 Billion USD | 5.48% |
2006 | 1.1 Billion USD | -0.38% |
2005 | 1.11 Billion USD | 399.92% |
2004 | 222.86 Million USD | 13.97% |
2003 | 195.54 Million USD | 10.08% |
2002 | 177.64 Million USD | -6.52% |
2001 | 190.03 Million USD | 42.48% |
2000 | 133.38 Million USD | -52.85% |
1999 | 282.9 Million USD | 12.98% |
1998 | 250.4 Million USD | 75.72% |
1997 | 142.5 Million USD | -15.28% |
1996 | 168.2 Million USD | -21.8% |
1995 | 215.1 Million USD | 19.83% |
1994 | 179.5 Million USD | 0.45% |
1993 | 178.7 Million USD | 34.16% |
1992 | 133.2 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 5.95 Billion USD | -1.46% |
2024 Q2 | 5.85 Billion USD | -1.7% |
2023 Q1 | 6.12 Billion USD | -0.88% |
2023 FY | 6.04 Billion USD | -2.17% |
2023 Q3 | 6.02 Billion USD | -1.57% |
2023 Q2 | 6.11 Billion USD | -0.08% |
2023 Q4 | 6.04 Billion USD | 0.35% |
2022 FY | 6.17 Billion USD | 17.09% |
2022 Q3 | 6.07 Billion USD | 0.08% |
2022 Q2 | 6.06 Billion USD | 14.85% |
2022 Q1 | 5.28 Billion USD | 0.21% |
2022 Q4 | 6.17 Billion USD | 1.65% |
2021 Q3 | 5.73 Billion USD | 0.25% |
2021 Q1 | 5.76 Billion USD | -1.14% |
2021 Q4 | 5.27 Billion USD | -8.01% |
2021 FY | 5.27 Billion USD | -9.59% |
2021 Q2 | 5.71 Billion USD | -0.83% |
2020 Q1 | 5.61 Billion USD | 2.12% |
2020 Q2 | 6.21 Billion USD | 10.75% |
2020 Q4 | 5.83 Billion USD | 1.35% |
2020 Q3 | 5.75 Billion USD | -7.43% |
2020 FY | 5.83 Billion USD | 6.11% |
2019 Q4 | 5.49 Billion USD | -0.98% |
2019 Q2 | 5.7 Billion USD | 5.23% |
2019 Q1 | 5.41 Billion USD | 1.95% |
2019 FY | 5.49 Billion USD | 3.42% |
2019 Q3 | 5.55 Billion USD | -2.64% |
2018 Q3 | 5.28 Billion USD | -0.85% |
2018 Q2 | 5.32 Billion USD | -1.95% |
2018 Q4 | 5.31 Billion USD | 0.61% |
2018 Q1 | 5.43 Billion USD | -0.44% |
2018 FY | 5.31 Billion USD | -2.62% |
2017 Q1 | 7.91 Billion USD | -0.01% |
2017 FY | 5.45 Billion USD | -31.02% |
2017 Q4 | 5.45 Billion USD | -5.91% |
2017 Q3 | 5.8 Billion USD | 1.57% |
2017 Q2 | 5.71 Billion USD | -27.82% |
2016 Q2 | 9.63 Billion USD | -0.68% |
2016 Q3 | 8.79 Billion USD | -8.69% |
2016 Q4 | 7.91 Billion USD | -10.05% |
2016 FY | 7.91 Billion USD | -12.64% |
2016 Q1 | 9.7 Billion USD | 3.66% |
2015 FY | 9.05 Billion USD | 74.64% |
2015 Q3 | 8.97 Billion USD | -0.96% |
2015 Q4 | 9.35 Billion USD | 4.31% |
2015 Q2 | 9.05 Billion USD | 37.3% |
2015 Q1 | 6.59 Billion USD | -2.2% |
2014 FY | 5.18 Billion USD | 71.84% |
2014 Q2 | 5.18 Billion USD | 0.05% |
2014 Q4 | 6.74 Billion USD | 33.2% |
2014 Q3 | 5.06 Billion USD | -2.36% |
2014 Q1 | 5.18 Billion USD | -0.53% |
2013 Q1 | 2.27 Billion USD | 3.87% |
2013 FY | 3.01 Billion USD | 39.0% |
2013 Q4 | 5.21 Billion USD | 71.5% |
2013 Q3 | 3.03 Billion USD | 0.69% |
2013 Q2 | 3.01 Billion USD | 32.93% |
2012 FY | 2.17 Billion USD | 30.95% |
2012 Q4 | 2.18 Billion USD | 1.57% |
2012 Q3 | 2.15 Billion USD | -0.89% |
2012 Q2 | 2.17 Billion USD | -4.23% |
2012 Q1 | 2.26 Billion USD | -1.92% |
2011 Q4 | 2.31 Billion USD | 17.37% |
2011 Q1 | 1.61 Billion USD | -0.9% |
2011 Q2 | 1.65 Billion USD | 2.84% |
2011 Q3 | 1.96 Billion USD | 18.78% |
2011 FY | 1.65 Billion USD | -17.26% |
2010 Q4 | 1.62 Billion USD | 3.83% |
2010 Q2 | 2 Billion USD | 34.36% |
2010 Q1 | 1.49 Billion USD | -5.52% |
2010 FY | 2 Billion USD | 24.14% |
2010 Q3 | 1.56 Billion USD | -21.81% |
2009 Q4 | 1.57 Billion USD | 3.39% |
2009 Q2 | 1.61 Billion USD | 5.44% |
2009 Q3 | 1.52 Billion USD | -5.41% |
2009 Q1 | 1.53 Billion USD | -4.3% |
2009 FY | 1.61 Billion USD | -1.64% |
2008 Q1 | 1.33 Billion USD | 9.31% |
2008 Q3 | 1.6 Billion USD | -2.21% |
2008 FY | 1.64 Billion USD | 40.21% |
2008 Q2 | 1.64 Billion USD | 22.78% |
2008 Q4 | 1.59 Billion USD | -0.32% |
2007 Q1 | 1.18 Billion USD | 2.02% |
2007 FY | 1.17 Billion USD | 5.48% |
2007 Q2 | 1.17 Billion USD | -1.23% |
2007 Q3 | 1.17 Billion USD | 0.4% |
2007 Q4 | 1.22 Billion USD | 4.04% |
2006 Q4 | 1.16 Billion USD | 0.67% |
2006 Q3 | 1.15 Billion USD | 3.98% |
2006 Q2 | 1.1 Billion USD | 6.06% |
2006 Q1 | 1.04 Billion USD | -2.96% |
2006 FY | 1.1 Billion USD | -0.38% |
2005 Q3 | 1.09 Billion USD | -1.41% |
2005 Q4 | 1.07 Billion USD | -1.82% |
2005 Q2 | 1.11 Billion USD | -0.72% |
2005 Q1 | 1.12 Billion USD | 430.81% |
2005 FY | 1.11 Billion USD | 399.92% |
2004 Q2 | 222.86 Million USD | 1.41% |
2004 FY | 222.86 Million USD | 13.97% |
2004 Q3 | 206.2 Million USD | -7.47% |
2004 Q4 | 211.41 Million USD | 2.53% |
2004 Q1 | 219.77 Million USD | 7.15% |
2003 Q2 | 195.54 Million USD | 2.71% |
2003 Q3 | 186.93 Million USD | -4.41% |
2003 Q1 | 190.39 Million USD | 4.75% |
2003 FY | 195.54 Million USD | 10.08% |
2003 Q4 | 205.1 Million USD | 9.72% |
2002 Q4 | 181.76 Million USD | -5.44% |
2002 Q2 | 177.64 Million USD | 11.84% |
2002 Q1 | 158.83 Million USD | -2.95% |
2002 FY | 177.64 Million USD | -6.52% |
2002 Q3 | 192.21 Million USD | 8.2% |
2001 Q4 | 163.66 Million USD | -19.98% |
2001 Q3 | 204.53 Million USD | 7.63% |
2001 Q2 | 190.03 Million USD | 12.84% |
2001 Q1 | 168.4 Million USD | 7.08% |
2001 FY | 190.03 Million USD | 42.48% |
2000 FY | 133.38 Million USD | -52.85% |
2000 Q2 | 133.38 Million USD | -8.75% |
2000 Q1 | 146.18 Million USD | -35.58% |
2000 Q4 | 157.26 Million USD | -0.45% |
2000 Q3 | 157.97 Million USD | 18.44% |
1999 FY | 282.9 Million USD | 12.98% |
1999 Q3 | 266.1 Million USD | -5.94% |
1999 Q4 | 226.9 Million USD | -14.73% |
1999 Q2 | 282.9 Million USD | -19.47% |
1999 Q1 | 351.3 Million USD | -8.73% |
1998 Q4 | 384.9 Million USD | 21.88% |
1998 Q3 | 315.8 Million USD | 26.12% |
1998 FY | 250.4 Million USD | 75.72% |
1998 Q2 | 250.4 Million USD | 15.55% |
1998 Q1 | 216.7 Million USD | -0.18% |
1997 Q4 | 217.1 Million USD | 15.36% |
1997 FY | 142.5 Million USD | -15.28% |
1997 Q3 | 188.2 Million USD | 32.07% |
1997 Q2 | 142.5 Million USD | -2.06% |
1997 Q1 | 145.5 Million USD | -8.38% |
1996 FY | 168.2 Million USD | -21.8% |
1996 Q1 | 189.3 Million USD | -17.26% |
1996 Q2 | 168.2 Million USD | -11.15% |
1996 Q3 | 179.8 Million USD | 6.9% |
1996 Q4 | 158.8 Million USD | -11.68% |
1995 Q3 | 241.3 Million USD | 12.18% |
1995 Q2 | 215.1 Million USD | -0.32% |
1995 Q1 | 215.8 Million USD | 17.09% |
1995 FY | 215.1 Million USD | 19.83% |
1995 Q4 | 228.8 Million USD | -5.18% |
1994 Q4 | 184.3 Million USD | -6.07% |
1994 FY | 179.5 Million USD | 0.45% |
1994 Q1 | 180.7 Million USD | -3.83% |
1994 Q2 | 179.5 Million USD | -0.66% |
1994 Q3 | 196.2 Million USD | 9.3% |
1993 Q3 | 207.1 Million USD | 15.89% |
1993 FY | 178.7 Million USD | 34.16% |
1993 Q1 | 166.2 Million USD | 6.2% |
1993 Q2 | 178.7 Million USD | 7.52% |
1993 Q4 | 187.9 Million USD | -9.27% |
1992 Q3 | 152.7 Million USD | 14.64% |
1992 Q1 | 121.7 Million USD | 67.4% |
1992 FY | 133.2 Million USD | 0.0% |
1992 Q2 | 133.2 Million USD | 9.45% |
1992 Q4 | 156.5 Million USD | 2.49% |
1991 Q4 | 72.7 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Editas Medicine, Inc. | 150.05 Million USD | -3925.964% |
Dynavax Technologies Corporation | 375.02 Million USD | -1510.884% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -1139.32% |
Illumina, Inc. | 4.36 Billion USD | -38.369% |
Thermo Fisher Scientific Inc. | 51.88 Billion USD | 88.356% |
Iovance Biotherapeutics, Inc. | 195.73 Million USD | -2986.371% |
Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 91.226% |
IQVIA Holdings Inc. | 20.56 Billion USD | 70.63% |
Heron Therapeutics, Inc. | 256.47 Million USD | -2255.437% |
Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 14.998% |
Unity Biotechnology, Inc. | 37.29 Million USD | -16099.721% |
Waters Corporation | 3.47 Billion USD | -73.772% |
Biogen Inc. | 12.04 Billion USD | 49.846% |
Sangamo Therapeutics, Inc. | 82.43 Million USD | -7228.618% |
Evolus, Inc. | 209.68 Million USD | -2781.056% |
Adicet Bio, Inc. | 37.12 Million USD | -16174.784% |
Cara Therapeutics, Inc. | 68.75 Million USD | -8686.05% |
bluebird bio, Inc. | 424.62 Million USD | -1322.718% |
Esperion Therapeutics, Inc. | 660.79 Million USD | -814.239% |
FibroGen, Inc. | 585.72 Million USD | -931.4% |
Agilent Technologies, Inc. | 4.91 Billion USD | -22.839% |
Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -17073.665% |
Homology Medicines, Inc. | 118.53 Million USD | -4996.64% |
Geron Corporation | 146.12 Million USD | -4034.212% |
Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -49.146% |
Amicus Therapeutics, Inc. | 617.7 Million USD | -878.006% |
Myriad Genetics, Inc. | 312.9 Million USD | -1830.713% |
Viking Therapeutics, Inc. | 20.07 Million USD | -29999.148% |
Intellia Therapeutics, Inc. | 250.8 Million USD | -2308.695% |
Zoetis Inc. | 9.29 Billion USD | 35.006% |
Abeona Therapeutics Inc. | 49.17 Million USD | -12184.854% |
Mettler-Toledo International Inc. | 3.5 Billion USD | -72.335% |
BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -219.631% |
Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | -17.309% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -12370.224% |
Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -132.052% |
Atara Biotherapeutics, Inc. | 264.73 Million USD | -2181.98% |
Verastem, Inc. | 71.18 Million USD | -8386.619% |
Nektar Therapeutics | 267.04 Million USD | -2162.232% |
Axsome Therapeutics, Inc. | 397.25 Million USD | -1420.721% |
Aclaris Therapeutics, Inc. | 40.22 Million USD | -14918.147% |
Sarepta Therapeutics, Inc. | 2.4 Billion USD | -151.168% |
OPKO Health, Inc. | 622.47 Million USD | -870.507% |
Exelixis, Inc. | 678.44 Million USD | -790.448% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | -492.623% |
Corcept Therapeutics Incorporated | 114.81 Million USD | -5161.819% |
Anavex Life Sciences Corp. | 12.53 Million USD | -48098.5% |
uniQure N.V. | 624.01 Million USD | -868.112% |
Imunon, Inc. | 8.53 Million USD | -70719.433% |
Blueprint Medicines Corporation | 918.64 Million USD | -557.624% |
Insmed Incorporated | 1.66 Billion USD | -263.542% |
Halozyme Therapeutics, Inc. | 1.64 Billion USD | -266.253% |
Agios Pharmaceuticals, Inc. | 126.09 Million USD | -4690.839% |
TG Therapeutics, Inc. | 169.08 Million USD | -3472.878% |
Incyte Corporation | 1.59 Billion USD | -279.408% |
Emergent BioSolutions Inc. | 1.18 Billion USD | -409.548% |